Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection (HS627) and Perjeta ® in Healthy Male Subjects: a Randomized, Double-blind, Parallelity-controlled Study

NCT04820439 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT04820439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04820439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection (HS627) and Perjeta ® in Healthy Male Subjects: a Randomized, Double-blind, Parallelity-controlled Study
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2020
Completion date
March 13, 2021
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers